Nido Biosciences

About Nido Biosciences

Nido Biosciences is a company focused on translating neuroscience breakthroughs into treatments for severe neurological diseases. They leverage human genetics to develop precision medicines that address the fundamental biology of disease and restore healthy cell function. Led by drug development and neuroscience experts, along with world-class scientific advisors and an industry-leading investor syndicate, their mission is to improve the daily lives of patients.

Products & Services

NIDO-361:A clinical-stage program in Phase 2 for the treatment of Spinal and Bulbar Muscular Atrophy (SBMA), also known as Kennedy's disease. It is a novel small molecule targeting the androgen receptor to restore healthy cell function.

2 Year Observational Study for SBMA:A completed observational study for Spinal and Bulbar Muscular Atrophy (SBMA).

Undisclosed Program for ALS:A preclinical proof-of-concept program targeting autophagy, cell death, and neuroinflammation for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease.

Functional Genetic Screens for ALS:A discovery-stage program identifying novel targets for Amyotrophic Lateral Sclerosis (ALS).

Additional Pipeline Programs:Programs focusing on a novel target to address multiple disease mechanisms across neurodegenerative and peripheral inflammatory diseases, using small molecule modulators to activate autophagy and inhibit neuroinflammation and cell death.

Functional Genomics Discovery Platform:A platform based on human iPSC-derived neurons and tailored screens to identify novel therapeutic targets for neurological diseases, with initial focus on ALS and FTD.

Specialties

Precision Medicine Neurological Diseases Human Genetics Functional Genomics Neurodegenerative Diseases Peripheral Inflammatory Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed, Series A, Series B T: - FT: Seed, Series A, Series B	A: 109000000 MR: - FA: 109 million FAN: 109000000	D: 2023-05-15 FD: 2023-05-15	6 investors

Seed, Series A, Series B Latest

2023-05-15

$109.0M

6 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jeremy Springhorn

Chief Executive Officer

V

Vissia Viglietta

Chief Medical Officer

M

Marc Swikalus

Vice President of Finance

M

Mike Clayman, M.D.

Chairman

D

Deborah Palestrant

Director

J

Jackie Grant, Ph.D.

Director

View 15 more team members with Pro

Unlock Full Team Directory

Recent News